mConsent to Resell iCoreRx Cloud ePrescribing Solution by iCoreConnect
iCoreConnect Inc. (NASDAQ: ICCT) has announced a new reseller agreement with mConsent, a leader in digital patient engagement solutions. This partnership allows mConsent to offer iCoreRx, iCoreConnect's premier electronic prescribing software, as part of its suite of digital solutions for dental practices.
The collaboration aims to enhance mConsent's Patient Engagement Platform by integrating iCoreRx, which is designed to streamline prescription workflows and improve patient safety. iCoreRx offers features such as real-time drug interaction checks, automatic updates, and integration with various practice management systems.
This strategic partnership is expected to expand the reach of iCoreRx and provide dental professionals with a more comprehensive set of tools to improve efficiency and patient care.
iCoreConnect Inc. (NASDAQ: ICCT) ha annunciato un nuovo accordo di rivendita con mConsent, leader nelle soluzioni di coinvolgimento digitale dei pazienti. Questa partnership consente a mConsent di offrire iCoreRx, il software di prescrizione elettronica di punta di iCoreConnect, come parte della sua suite di soluzioni digitali per studi dentistici.
La collaborazione mira a potenziare la Piattaforma di Coinvolgimento dei Pazienti di mConsent integrando iCoreRx, progettato per ottimizzare i flussi di lavoro delle prescrizioni e migliorare la sicurezza del paziente. iCoreRx offre funzionalità come controlli in tempo reale delle interazioni tra farmaci, aggiornamenti automatici e integrazione con vari sistemi di gestione dello studio.
Questa partnership strategica si prevede ampliarà la portata di iCoreRx e fornirà ai professionisti dentali un set di strumenti più completo per migliorare l'efficienza e la cura del paziente.
iCoreConnect Inc. (NASDAQ: ICCT) ha anunciado un nuevo acuerdo de reventa con mConsent, líder en soluciones de compromiso digital del paciente. Esta asociación permite a mConsent ofrecer iCoreRx, el software de prescripción electrónica premium de iCoreConnect, como parte de su conjunto de soluciones digitales para prácticas dentales.
La colaboración tiene como objetivo mejorar la Plataforma de Compromiso del Paciente de mConsent al integrar iCoreRx, que está diseñado para optimizar los flujos de trabajo de prescripción y mejorar la seguridad del paciente. iCoreRx ofrece características como verificaciones en tiempo real de interacciones medicamentosas, actualizaciones automáticas e integración con varios sistemas de gestión de prácticas.
Se espera que esta asociación estratégica amplíe el alcance de iCoreRx y proporcione a los profesionales dentales un conjunto de herramientas más completo para mejorar la eficiencia y la atención al paciente.
iCoreConnect Inc. (NASDAQ: ICCT)는 디지털 환자 참여 솔루션의 선두주자인 mConsent와 새로운 리셀러 계약을 발표했습니다. 이 파트너십을 통해 mConsent는 iCoreConnect의 주요 전자 처방 소프트웨어인 iCoreRx를 치과 클리닉을 위한 디지털 솔루션 패키지의 일부로 제공할 수 있습니다.
협력의 목적은 iCoreRx를 통합하여 mConsent의 환자 참여 플랫폼을 강화하는 것으로, 처방 업무 흐름을 간소화하고 환자 안전을 향상시키도록 설계되었습니다. iCoreRx는 실시간 약물 상호작용 확인, 자동 업데이트 및 다양한 진료 관리 시스템과의 통합과 같은 기능을 제공합니다.
이 전략적 파트너십은 iCoreRx의 범위를 확대하고 치과 전문의에게 효율성과 환자 치료를 개선하기 위한 보다 포괄적인 도구 세트를 제공할 것으로 기대됩니다.
iCoreConnect Inc. (NASDAQ: ICCT) a annoncé un nouvel accord de revente avec mConsent, un leader des solutions d'engagement digital des patients. Ce partenariat permet à mConsent d'offrir iCoreRx, le logiciel de prescription électronique phare d'iCoreConnect, comme partie de son ensemble de solutions numériques pour les cabinets dentaires.
La collaboration vise à améliorer la Plateforme d'Engagement Patient de mConsent en intégrant iCoreRx, conçu pour rationaliser les flux de travail de prescription et améliorer la sécurité des patients. iCoreRx offre des fonctionnalités telles que des vérifications en temps réel des interactions médicamenteuses, des mises à jour automatiques et une intégration avec divers systèmes de gestion de cabinet.
Ce partenariat stratégique devrait élargir la portée d'iCoreRx et fournir aux professionnels dentaires un ensemble d'outils plus complet pour améliorer l'efficacité et les soins aux patients.
iCoreConnect Inc. (NASDAQ: ICCT) hat eine neue Wiederverkäufervereinbarung mit mConsent, einem führenden Anbieter von digitalen Lösungen zur Patientenengagement, bekannt gegeben. Diese Partnerschaft ermöglicht es mConsent, iCoreRx, die Spitzenlösung für elektronische Verschreibungen von iCoreConnect, als Teil seines Portfolios an digitalen Lösungen für Zahnarztpraxen anzubieten.
Die Zusammenarbeit zielt darauf ab, die Patientenengagement-Plattform von mConsent durch die Integration von iCoreRx zu verbessern, das Entwickelt wurde, um Verschreibungsabläufe zu optimieren und die Patientensicherheit zu erhöhen. iCoreRx bietet Funktionen wie Echtzeit-Überprüfungen von Arzneimittelinteraktionen, automatische Aktualisierungen und die Integration mit verschiedenen Praxisverwaltungssystemen.
Diese strategische Partnerschaft wird voraussichtlich die Reichweite von iCoreRx erweitern und zahnmedizinischen Fachkräften ein umfassenderes Set an Werkzeugen zur Verbesserung der Effizienz und Patientenversorgung bereitstellen.
- New reseller agreement expands distribution of iCoreRx ePrescribing software
- Partnership enhances mConsent's product offerings for dental practices
- Potential for increased market reach and customer base for iCoreConnect
- None.
Insights
This partnership between iCoreConnect and mConsent represents a strategic move in the dental software market. By integrating iCoreRx into mConsent's Patient Engagement Platform, both companies stand to benefit:
- iCoreConnect gains expanded market reach for iCoreRx
- mConsent enhances its product offering, potentially increasing its competitive edge
- Dental practices receive a more comprehensive, integrated solution
The collaboration aligns with the trend of consolidation and integration in healthcare technology, potentially leading to increased market share for both companies. However, the financial impact remains uncertain without specific revenue projections or deal terms. Investors should monitor future financial reports for tangible results from this partnership.
The integration of iCoreRx into mConsent's platform addresses a critical need in dental practices: streamlined workflow and enhanced patient safety. Key benefits include:
- Real-time drug interaction checks, reducing medication errors
- Compliance with ePrescribing regulations, mitigating legal risks
- Integration with practice management systems, improving operational efficiency
This partnership reflects the growing importance of interoperability in healthcare IT. By offering a more comprehensive solution, mConsent and iCoreConnect are positioning themselves at the forefront of the digital transformation in dentistry. The success of this venture will likely depend on the seamless integration of iCoreRx and its adoption rate among mConsent's existing clientele.
Strategic Partnership Enhances Patient Engagement Platform with Advanced iCoreRx ePrescribing Software
OCOEE, FL, Aug. 05, 2024 (GLOBE NEWSWIRE) -- iCoreConnect Inc. (NASDAQ: ICCT) (“iCore” or the “Company”), a leading cloud-based software and technology company, today announced a new reseller agreement with mConsent, a leader in digital patient intake, patient communication and engagement solutions. Through this partnership, mConsent will now offer iCoreConnect's premier electronic prescribing software, iCoreRx, as part of its suite of digital solutions.
This collaboration allows mConsent to expand its offerings by providing dental practices with iCoreRx, an advanced ePrescribing software designed to streamline prescription workflows and enhance patient safety. By integrating iCoreRx into their product lineup, mConsent can deliver a more comprehensive set of tools to improve the efficiency and effectiveness of their Patient Engagement Platform.
"We are excited to partner with mConsent and expand the reach of iCoreRx," said Robert McDermott, CEO of iCoreConnect. "mConsent's commitment to innovation and excellence aligns perfectly with our mission to provide superior software solutions for dental practices. This partnership will enable us to bring the benefits of iCoreRx to a wider audience."
iCoreRx is known for its user-friendly interface and secure, cloud-based platform that simplifies the ePrescribing process. The software ensures compliance with the latest ePrescribing regulations and offers features such as real-time drug interaction checks, automatic updates, and integration with various practice management systems. By adding iCoreRx to its offerings, mConsent can help dental professionals reduce errors, save time, and improve patient outcomes.
"We are thrilled to become a reseller of iCoreRx," said Samad Syed, CEO of mConsent. "This partnership with iCoreConnect enables us to offer a robust electronic prescribing solution that complements our entire suite of patient engagement solutions. Together, we can provide dental practices with a seamless, integrated experience that enhances patient care and operational efficiency."
About iCoreConnect Inc. (NASDAQ: ICCT)
iCoreConnect Inc. is a leading, cloud-based software and technology company focused on increasing workflow productivity and practice profitability through its enterprise and healthcare workflow platform of applications and services. iCoreConnect is most notably known for its innovation in solving healthcare business problems. iCoreConnect’s philosophy places a high value on customer feedback, positioning iCoreConnect to respond to the market’s needs. iCoreConnect touts a platform of 16 SaaS enterprise solutions and more than 130 product endorsements with state or regional healthcare associations across the United States.
About mConsent
mConsent, recognized as INC 5000 fastest growing SaaS platform for dental practices, is a full-service patient engagement platform that is currently used by over 5 million patients across the United States. It is a one-stop-solution for dental practices that want to automate their operational workflow for a seamless patient experience. From patient intake to patient communication and engagement, mConsent places a high level of emphasis on empowering office staff to move away from administrative activities for a more patient centric experience. An average practice using mConsent saves ~
Forward-Looking Statements
Some of the statements in this release are forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, Section 21E of the Securities Exchange Act of 1934 and the Private Securities Litigation Reform Act of 1995, which involve risks and uncertainties. Although the Company believes that the expectations reflected in such forward-looking statements are reasonable as of the date made, expectations may prove to have been materially different from the results expressed or implied by such forward-looking statements. The Company has attempted to identify forward-looking statements by terminology including ‘believes,’ ‘estimates,’ ‘anticipates,’ ‘expects,’ ‘plans,’ ‘projects,’ ‘intends,’ ‘potential,’ ‘may,’ ‘could,’ ‘might,’ ‘will,’ ‘should,’ ‘approximately’ or other words that convey uncertainty of future events or outcomes to identify these forward-looking statements. These statements are only predictions and involve known and unknown risks, uncertainties, and other factors, including those discussed under Item 1A. “Risk Factors” in the Company’s most recently filed Form 10-K filed with the Securities and Exchange Commission (“SEC”) and updated from time to time in its Form 10-Q filings and in its other public filings with the SEC. Any forward-looking statements contained in this release speak only as of its date. The Company undertakes no obligation to update any forward-looking statements contained in this release to reflect events or circumstances occurring after its date or to reflect the occurrence of unanticipated events.
Media Contact:
ir@icoreConnect.com
888.810.7706 ext.5
FAQ
What is the new partnership announced by iCoreConnect (ICCT)?
What are the key features of iCoreRx mentioned in the press release?
How does this partnership benefit dental practices using mConsent's services?
When was the reseller agreement between iCoreConnect (ICCT) and mConsent announced?
